News Activity: Performance Sports Group (NYSE:PSG), StoneMor Partners L.P. (NYSE:STON), Ensco plc (NYSE:ESV), ViewRay (NASDAQ:VRAY), Pain Therapeutics (NASDAQ:PTIE)

Performance Sports Group Ltd. (NYSE:PSG) shares fell -0.78% in last trading session and ended the day at $3.82. Performance Sports Group Ltd. (NYSE:PSG) quarterly performance is -46.27%.

Performance Sports Group (NYSE: PSG) reported Q3 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $126.1 million versus the consensus estimate of $124.44 million. GUIDANCE: Performance Sports Group sees Q4 2016 EPS of $0.18-$0.20, versus the consensus of $0.15.

StoneMor Partners L.P. (NYSE:STON) ended the last trading day at $24.65. Company weekly volatility is calculated as 1.96% and price to cash ratio as 52.98. StoneMor Partners L.P. (NYSE:STON) showed a weekly performance of -0.64%.

StoneMor Partners L.P. (NYSE: STON) announced a public offering, subject to market and other conditions, of 2,000,000 common units representing limited partner interests in StoneMor.

On 14 April, Ensco plc (NYSE:ESV) shares fell -4.94% and was closed at $10.59. ESV EPS growth in last 5 year was -29.50%. Ensco plc (NYSE:ESV) year to date (YTD) performance is -31.12%.

Ensco plc (NYSE: ESV) commenced an underwritten public offering of 50,000,000 Class A ordinary shares. Also disclosed in an SEC filing: Ensco plc is furnishing the following preliminary estimated financial information for the quarter ended March 31, 2016: • Operating revenues are expected to be between $812 million and $817 million, benefiting from estimated reported utilization between 64% and 66%, as compared to the low-60% range in our first quarter 2016 outlook disclosed on our February 25, 2016 conference call, and average day rates that declined by approximately 3% to 4%, as compared to a 7% to 8% decline in our prior disclosed outlook. (Street sees Q1 revenue of $793.05 million). • Contract drilling expense is anticipated to be between $361 million and $366 million, as compared to our prior disclosed outlook of $385 million to $390 million.

ViewRay, Inc. (NASDAQ:VRAY) shares remains unchanged in last trading session and ended the day at $4.65.

ViewRay, Inc. (NASDAQ:VRAY) announced the appointment of Henry A. McKinnell, Jr., Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., to the company’s Board of Directors.

Pain Therapeutics Inc. (NASDAQ:PTIE) caters to the Healthcare space. Its weekly performance is 6.51%. On the last day of trading company shares ended up at $2.29. Pain Therapeutics Inc. (NASDAQ:PTIE) distance from 50-day simple moving average (SMA50) is -1.01%.

Pain Therapeutics, Inc. (NASDAQ: PTIE) announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) resubmission for REMOXY®, an abuse-deterrent formulation of extended-release oxycodone (CII) capsules, is sufficiently complete to permit a substantive review. September 25, 2016 is the target action date under the Prescription Drug User Fee Act (PDUFA).